A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System


About this study

The purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring. In this study, the investigators will utilize the novel technology for circulating tumor cell detection in order to evaluate their presence in patients with lung cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Stage IB and above non-small cell lung cancer or metastatic lung cancer
  • Age >18 years old
  • Willing and able to consent to study
  • No prior history of neoadjuvant therapy.

Exclusion Criteria:

  • Age <18 years old
  • Unable to provide consent

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Dennis Wigle, M.D., Ph.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer